Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings

authors:

avatar Mashaallah Babashahi 1 , avatar Mitra Mehrazma 2 , * , avatar Seyed Javad Nasiri 3 , avatar Farid Azizi Jalilian 4 , avatar Mostafa Rezaei-Tavirani 5

Dept. of Pathology, Iran University of Medical Sciences, Tehran, Iran
Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
Dept. of Pathology , Ali-Asghar Children Hospital, Iran University of Medical Sciences, Tehran, Iran
Dept. of Medical Microbiology, Ilam University of Medical Sciences, Ilam, Iran
Proteomics Research Center, ShahidBeheshti University of Medical Sciences, Tehran, Iran

how to cite: Babashahi M, Mehrazma M , Nasiri S J, Azizi Jalilian F, Rezaei-Tavirani M. Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings. Int J Cancer Manag. 2013;6(3):e80429. 

Abstract

Background: Wilms' tumor is an emberyonal tumor arising from remnants of immature renal tissue. Her2/neu is an onco-protein which mediates cellular proliferation, differentiation and survival.
Methods: In the current study, we analyzed Her2/neu expression in 40 Wilms' tumors. The clinico-demographic data of 40 patients with Wilms' tumor were retrieved. Immunohistochemical staining for HER2/neu was performed. Her2/neuimmunoreactivity was evaluated by Canadian Consensus 2007 scoring system.
Results: Among the 38 specimens with epithelial component, 68.5% were positive for Her2/neu, whereas there was immunoreactivity in 37% of 38 blastemal, and 12% of 31 stromal components. The Her2/neu expression was significantly higher in early stages (81.5%) than in advanced stages (36.4%) in epithelial component, but not in other components.
Conclusion: This study suggested that Her2/neuexpression is associated with epithelial cell differentiation accompanied by lower stages of tumor. No significant relationship was found between Her2/neu positivity and tumor size and patient's age and gender.

Fulltext

The Full text is available in PDF.